Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
about
MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.Emerging drugs and therapeutics for systemic sclerosis.Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study.Cost-of-Illness in Rare Diseases.Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.Systemic sclerosis: state of the art on clinical practice guidelines
P2860
Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Social/economic costs and heal ...... ts with scleroderma in Europe.
@en
Social/economic costs and heal ...... ts with scleroderma in Europe.
@nl
type
label
Social/economic costs and heal ...... ts with scleroderma in Europe.
@en
Social/economic costs and heal ...... ts with scleroderma in Europe.
@nl
prefLabel
Social/economic costs and heal ...... ts with scleroderma in Europe.
@en
Social/economic costs and heal ...... ts with scleroderma in Europe.
@nl
P2093
P2860
P50
P1476
Social/economic costs and heal ...... nts with scleroderma in Europe
@en
P2093
Arrigo Schieppati
BURQOL-RD Research Network
Claudia Delgado
Georgi Iskrov
Giovanni Fattore
Johann Mathias von der Schulenburg
Julio López-Bastida
Karine Chevreul
Manuel Posada-de-la-Paz
Márta Péntek
P2860
P2888
P304
P356
10.1007/S10198-016-0789-Y
P478
17 Suppl 1
P577
2016-04-02T00:00:00Z